Endoscopic Submucosal Dissection for Recurrent or Residual Superficial Esophageal Cancer after Chemoradiotherapy: Two Cases.
	    		
		   		
		   			
		   		
	    	
    	- Author:
	        		
		        		
		        		
			        		Changhyeok HWANG
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Young Hoon YOUN
			        		
			        		;
		        		
		        		
		        		
			        		Sung Eun CHOI
			        		
			        		;
		        		
		        		
		        		
			        		Young Hak JUNG
			        		
			        		;
		        		
		        		
		        		
			        		Hae Yeul PARK
			        		
			        		;
		        		
		        		
		        		
			        		Jae Jun PARK
			        		
			        		;
		        		
		        		
		        		
			        		Jie Hyun KIM
			        		
			        		;
		        		
		        		
		        		
			        		Hyojin PARK
			        		
			        		
		        		
		        		
		        		
			        		
			        		Author Information
			        		
 - Publication Type:Case Report
 - Keywords: Esophageal neoplasms; Chemoradiotherapy; Endoscopic submucosal dissection
 - MeSH: Carcinoma, Squamous Cell; Chemoradiotherapy*; Endoscopy, Digestive System; Esophageal Neoplasms*; Follow-Up Studies; Humans; Middle Aged; Recurrence
 - From:Clinical Endoscopy 2015;48(6):553-557
 - CountryRepublic of Korea
 - Language:English
 - Abstract: We report two cases of endoscopic submucosal dissection (ESD) for recurrent or residual esophageal squamous cell carcinoma (ESCC) lesions after chemoradiotherapy for advanced esophageal cancer. Case 1 involved a 64-year-old man who had previously undergone chemoradiotherapy for advanced ESCC and achieved a complete response (CR) for 22 months, until metachronous recurrent superficial ESCC was detected on follow-up esophagogastroduodenoscopy (EGD). We performed ESD and found no evidence of recurrence for 24 months. Case 2 involved a 59-year-old man who had previously undergone chemoradiotherapy for advanced ESCC. He responded favorably to treatment, and most of the tumor had disappeared on follow-up EGD 4 months later. However, there were two residual superficial esophageal lugol-voiding lesions. We performed ESD, and he had a CR for 32 months thereafter. ESD can be considered a viable treatment option for recurrent or residual superficial ESCC after chemoradiotherapy for advanced esophageal cancer.
 
            